摘要
目的探讨肥胖对转移性前列腺癌去势抵抗的影响。方法纳入江苏省如皋市人民医院2010年1月～2016年6月收治的41例初诊转移性前列腺癌患者为研究对象。收集41例患者的临床病理数据，并对其进行随访。体重指数（BMI）〈25kg／m2为正常体重组20例，BMI≥25kg/m2为肥胖组21例。研究对象随访资料应用SPSS16．0软件进行统计学分析。卡方检验分析体重指数与转移性前列腺癌患者临床病理参数的关系。使用Kaplan—Meier法对该组人群进行生存相关分析，统计量行Log—rank检验。预后危险因素的多因素分析采用Cox比例风险模型。结果入组患者中位无进展时间为30个月，体重正常组中位无进展生存时间为34个月，肥胖组中位无进展生存时间为14个月。Cox比例回归模型分析显示体重指数增加（HR1．879，95％CI：1．073～2．481，19=0．049）是转移性前列腺癌去势抵抗的危险因素。结论肥胖的转移性前列腺癌患者经最大限度雄激素阻断内分泌治疗后易较早出现去势抵抗。
Objective To explore the effect of obesity on castration resistance in metastatic prostate cancer. Methods Clinical data of 41 patients with metastatic prostate cancer in Rugao People＇s Hospital from January in 2010 to June in 2016 was retrospectively reviewed. The patients were divided into two groups according to body mass index （BMI）. The patients with BMI 〈25kg/ m2 were as the normal body weight group （20 cases）. The patients with BMI 〉25kg/m2 were as the obese group （21 cases）. Follow - up data was evaluated using SPSS 16. 0 software. Comparisons between BMI and clinicopathological indexes were assessed using Chi - square test. The survival analysis was evaluated using Kaplan - Meier and Log - rank. Multivariate analysis of prognostic risk factors was performed using Cox proportional hazard model. Results The overall median progression free survival was 30 months after androgen deprived therapy. The median progression free survival was 34 months in the normal body weight group, while it was 14 months in obese group. Cox proportional hazard model showed high BMI is a risk factor for castration resistance in patients with metastatic prostate cancer （ HR 1. 879, 95% CI ： 1. 073 - 2. 481, P = 0. 049）. Conclusion Early castration resistant more commonly occurs in obese patients with metastatic prostate cancer after treatment with maximal androgen blockage.
作者
李飞
石露
邢家龙
宗朝晖
郝建国
Li Fei;Shi Lu;Xing Jialong;Zong Chaohui;Hao Jianguo(Department of Urology,Rugao People＇s Hospital,NanTong 226500,China)
出处
《国际老年医学杂志》
2018年第5期219-221,共3页
International Journal of Geriatrics
关键词
肥胖
体重指数
转移性前列腺癌
去势抵抗性前列腺癌
治疗
预后
Obesity
Body mass index
Metastatic prostate cancer
Castration resistant prostate cancer
Therapy
Prognosis
